Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Immunovant (IMVT) Operating Expenses (2018 - 2026)

Immunovant filings provide 8 years of Operating Expenses readings, the most recent being $114.4 million for Q4 2025.

  • Quarterly Operating Expenses changed 0.05% to $114.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $487.2 million through Dec 2025, up 20.23% year-over-year, with the annual reading at $438.2 million for FY2025, 54.98% up from the prior year.
  • Operating Expenses hit $114.4 million in Q4 2025 for Immunovant, down from $131.8 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $131.8 million in Q3 2025 and bottomed at $28.9 million in Q1 2021.
  • Average Operating Expenses over 5 years is $74.9 million, with a median of $64.1 million recorded in 2022.
  • Peak annual rise in Operating Expenses hit 94.37% in 2023, while the deepest fall reached 3.86% in 2023.
  • Immunovant's Operating Expenses stood at $41.3 million in 2021, then surged by 55.14% to $64.0 million in 2022, then dropped by 3.86% to $61.6 million in 2023, then surged by 85.7% to $114.3 million in 2024, then rose by 0.05% to $114.4 million in 2025.
  • Per Business Quant, the three most recent readings for IMVT's Operating Expenses are $114.4 million (Q4 2025), $131.8 million (Q3 2025), and $127.2 million (Q2 2025).